Viewing stories from April, 2015

30 April 2015
Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2015.

Read More

30 April 2015
DEP™ Docetaxel Trial Dose Exceeds Common Taxotere® Dose Level

Starpharma today released an update to the progress of its phase 1 clinical trial of DEP™ docetaxel for advanced solid cancers. The DEP™ docetaxel dose level now exceeds the most commonly used dose for Taxotere® of 75mg/m2, with no dose limiting toxicities (DLT), including neutropenia, having been observed to date.

Read More

27 April 2015
Herald Sun: Star turn for Carlton and United Breweries

The Herald Sun's Paul Glider reports that "beer and biotechnology does not sound like a recipe for success but it's a match made in hoppy heaven for the research team at Starpharma".

 

Go to the article (external link)

Read More

8 April 2015
Channel 9 News: Starpharma’s DEP™ docetaxel drug

The benefits of Starpharma’s DEP™ docetaxel drug which is currently in clinical trials, has been featured nationally on Channel 9 News.

 

Watch the video (external link)

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.